Note: The content of this article is current to the time of its posting on February 10, 2016. Please continue to check our site for the latest information on generics. LRG Research Program to track efficacy On February 1, 2016, the commercial launch of the generic version of imatinib mesylate (Gleevec), for CML (Chronic Myeloid […]
With the onset of the patent expiration on Gleevec of the patent expiration on Gleevec for CML expiring in July and for GIST in June 2022 in the United States, it becomes more important than ever to understand the implications when a brand name drug becomes available as a generic. Navigating the waters of generic vs. brand […]
Many new cancer drugs are entering clinical practice and clinical trials. Many GIST patients are no longer responding to Gleevec or Sutent and thus are looking for clinical trials. Understanding strategies and grouping these new drugs into classes with other similar drugs may help patients understand some of their choices.
Pfizer Pharmaceuticals is offering Sutent in Touch, a program to support GIST patients on its drug Sutent. The program is free and patients can sign up by calling (1-877-578-8368). Sutent in Touch links patients to Oncology Certified Nurses by telephone, mail and e-mail, providing answers to questions about treatment and side effects. The nurses work together […]
Trial investigators for the Global Phase 3 GRID trial reported that the Bayer Pharmaceuticals’ drug regorafenib (BAY 73-4506) has the potential to fill the unmet need for advanced GIST patients progressing after imatinib and sunitinib. Dr. George Demetri of the Dana Farber Cancer Institute was the leading Principal Investigator and presented the data for the […]